Contract development and joint research with Fujifilm, Nidec, Osaka University and others
First written in FY2016. 9 of 17 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-10-30.
Japan Tissue Engineering moved to the "Worse" side of this theme in 2022.
1 other company's latest entry also says "Advanced".
- 2026-10-30AdvancedEarnings
「一方で、商用生産までを一気通貫で支援する独自の価値提供により、複数の顧客案件が治験製品製造や薬事支援を含む高付加価値フェーズへ移行しており、特定顧客に依存しない事業ポートフォリオへの転換が着実に進展しています。」
受託開発・製造の関係について、複数顧客案件が治験製品製造・薬事支援を含む高付加価値フェーズへ移行し、顧客ポートフォリオ分散が進んだと説明している。 - FY2026AdvancedAnnual report
「Projects with Actualize Co., Ltd., VC Cell Therapy Co., Ltd., Metcela Co., Ltd. and AlliedCel Co., Ltd. are steadily progressing, and we are moving toward a robust business portfolio that is not dependent on any particular customer.」
Our contract development and manufacturing relationships expanded to Actualize, VC Cell Therapy, Metcela and AlliedCel, advancing the shift toward a portfolio less dependent on any particular customer. - FY2026-H1AdvancedAnnual report
「We entered into an agreement with Metcela Co., Ltd. for the manufacture of investigational products for regenerative medicine products targeting functionally univentricular heart disease. In October 2025, we also entered into a contract manufacturing agreement for AlliedCel Co., Ltd.'s investigational induced regulatory T-cell product currently under development, on the assumption that we will undertake commercial manufacturing after its launch.」
In addition to existing contract relationships, including those involving Teijin, we expanded our contracting counterparties and technology areas to include an investigational product manufacturing agreement with Metcela and a contract manufacturing agreement with AlliedCel covering post-launch product manufacturing. - FY2024ReframedAnnual report
「Working with Teijin Regenerative Medicine Co., Ltd., established during the fiscal year, and other affiliated companies of the Teijin Group, we will contribute to society through the expansion of our CDMO business.」
The relationship is being reorganized from the existing contract development arrangements with Fujifilm, Nidec, Osaka University and others toward a relationship centered on CDMO collaboration with the Teijin Group, particularly Teijin Regenerative Medicine. - FY2022-Q3SoftenedAnnual report
「Following this, we held repeated discussions with Fujifilm regarding our contract development work for the company, agreed not to continue the work and decided to discontinue the business relationship. The handover is scheduled to be completed within the current fiscal year. Accordingly, we are preparing to allocate the personnel capacity and space becoming available in the regenerative medicine contract business to new contracts from Teijin and third parties, and expect revenue from these contracts to be added from the next fiscal year.」
We agreed not to continue contract development work for Fujifilm and plan to discontinue the business relationship and complete the handover. At the same time, we are preparing to allocate the available personnel capacity and space to new contracts from Teijin and third parties. - FY2020RestatedAnnual report
「We will continue to aim for business expansion by steadily advancing projects undertaken independently under contract, while also providing process development and regulatory consulting services for regenerative medicine products to regenerative medicine ventures invested in by Fujifilm.」
In addition to projects sourced independently, we continue to pursue contract process development and regulatory consulting services for regenerative medicine ventures invested in by Fujifilm as a means of expanding the business. - FY2020-Q3RestatedAnnual report
「We will continue to aim for business expansion by steadily advancing projects undertaken independently under contract, while also providing process development and regulatory consulting services for regenerative medicine products to regenerative medicine ventures invested in by Fujifilm.」
In addition to projects sourced independently, we continue to pursue contract process development and regulatory consulting services for regenerative medicine ventures invested in by Fujifilm as a means of expanding the business. - FY2020-Q2RestatedAnnual report
「Going forward, we aim to expand the business by steadily advancing projects undertaken independently under contract and by providing process development and regulatory consulting services for regenerative medicine products to regenerative medicine ventures invested in by Fujifilm.」
In addition to projects sourced independently, we continue to pursue contract process development and regulatory consulting services for regenerative medicine ventures invested in by Fujifilm as a means of expanding the business. - FY2019AdvancedAnnual report
「The contract period was extended by 3 years under a memorandum of understanding executed on 25 March 2019.」
The term of the master services agreement for contract research and development of regenerative medicine products for Fujifilm was extended by 3 years under a memorandum of understanding. - FY2019-Q2AdvancedAnnual report
「This was driven by milestone payments received as contracted research projects reached key stages, as well as growth in new orders for development consulting and contract development and manufacturing of regenerative medicine products from companies and academic institutions.」
Milestone payments received as contracted research projects reached key stages, together with growth in new contracts from companies and academic institutions, contributed to higher revenue. - FY2018AdvancedAnnual report
「We undertook and advanced the development and manufacture of regenerative medicine products for several companies that we sourced independently, as well as academic institutions including The Jikei University School of Medicine and Hyogo Medical University.」
In addition to Fujifilm, Nidec, Osaka University and other existing clients, we advanced contract development and manufacturing projects sourced independently and projects for clients including The Jikei University School of Medicine and Hyogo Medical University. - FY2018-Q3AdvancedAnnual report
「We also undertook and advanced the development and manufacture of regenerative medicine products for multiple companies and academic institutions, including Cyfuse Biomedical K.K., in which Fujifilm has invested.」
We secured new contract development and manufacturing work for regenerative medicine products from multiple companies and academic institutions, including Cyfuse Biomedical K.K., in which Fujifilm has invested, and are advancing these projects. - FY2018-Q2AdvancedAnnual report
「We also secured contracts from many companies and academic institutions, including newly acquired clients such as RegCell Co., Ltd. and Hyogo Medical University, to support the development and manufacture of regenerative medicine products.」
In addition to our existing contracts with Fujifilm, Nidec, Osaka University and others, we secured new development and manufacturing support agreements with numerous companies and academic institutions, including RegCell Co., Ltd. and Hyogo Medical University. - FY2018-Q1AdvancedAnnual report
「We also newly secured several contracts relating to contract development and contract manufacturing of regenerative medicine products.」
In addition to existing contract development projects with Fujifilm, Nidec, Osaka University and others, we secured new contract development and manufacturing agreements for multiple regenerative medicine products. - FY2017-Q2RestatedAnnual report
「From 富士フイルム, we have accepted contract development of regenerative medicine products using a biocompatible recombinant peptide developed by 富士フイルム and are advancing their commercialisation.」
Regarding contract development from 富士フイルム, the company has specified that it is advancing the commercialisation of regenerative medicine products using a recombinant peptide, but no completed milestone that can be named is disclosed. - FY2017-Q1RestatedAnnual report
「In our regenerative medicine products business, we accept development projects from 富士フイルム, ニデック, and the Department of Ophthalmology at Osaka University.」
The company continues to accept development projects from 富士フイルム, ニデック, and the Department of Ophthalmology at Osaka University. - FY2016First statedAnnual report
「In addition to corneal epithelium development for ニデック, we have accepted multiple development projects from 富士フイルム and are advancing development toward next-generation products. We also undertake work from the Department of Ophthalmology at Osaka University relating to research on corneal regenerative medicine. We will promote the appropriate allocation of personnel and greater efficiency, steadily advance our existing product pipeline, and actively pursue exploratory research into new products.」
In addition to advancing the existing pipeline, the company is pursuing contract development and new product discovery through work from major shareholders, partners, and research institutions as growth drivers.